bristol myers squibb food and drug administration news

22hon MSN

Bristol Myers faces renewed, $6.7 billion lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

Bristol Myers faces renewed, $6.7 bln lawsuit over delayed cancer drug

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

4don MSN

Bristol Myers Squibb’s stock soars after rival AbbVie reports disappointing schizophrenia-drug trial

Bristol Myers Squibb Co. shares surged 12.5% Monday after rival AbbVie Inc. reported disappointing results from the trial of ...

3don MSN

AbbVie’s disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say

AbbVie Inc.’s disappointing trial results for its new schizophrenia drug bode well for rival Bristol Myers Squibb Co., ...

10h

Bristol Myers Gets CHMP Backing for Augtyro Cancer Drug

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

11h

FDA approves Cobenfy for adults with schizophrenia

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

What's Going On With Bristol-Myers Squibb Shares Monday?

Bristol-Myers Squibb Co (NYSE:BMY) shares are trading higher Monday. The stock appears to be reacting positively after AbbVie ...

Bristol's New Schizophrenia Drug Cobenfy Helps Support Its Wide Moat

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...